加拿大制藥行業(yè)市場前景及投資研究報(bào)告-培訓(xùn)課件外文版2024.4

INDUSTRIES

&

MARKETSCanadianpharmaceuticalindustryCHAPTER

01GlobalpositioningMarketshareofleading10nationalpharmaceuticalmarketsworldwidein2022Marketshareoftheleadingglobalpharmaceuticalmarkets2022Marketshare20%0%5%10%15%25%30%35%40%45%42.6%UnitedStatesChina*7.6%Japan4.5%GermanyFrance4%2.8%2.4%2.3%2%ItalyUnitedKingdomCanadaSpain1.9%1.9%Brazil**3Description:TheUnitedStateswasthelargestnationalpharmaceuticalmarketin2022,makingupover42percentofthetotalpharmaceuticalspendingworldwide.Chinaisthesecond-largestmarketwithamarketshareofaroundeightpercent(althoughincludingonlythehospitalmakret).ReadmoreNote(s):UnitedStatesSource(s):IQVIAGrowthrateoftop10nationalpharmaceuticalmarketsworldwidein2022Topglobalpharmaceuticalmarkets:growthrate2022Growthrate-5%0%5%10%15%20%Brazil**France17.7%10.3%10%ItalyCanada9.5%9.4%UnitedStatesSpain8%UnitedKingdomGermanyJapan6.3%5.4%2.6%China*-1.9%4Description:In2022,thegrowthrateofBrazil’spharmaceuticalmarketstoodatnearly18percent,whichwassignificanthigherthanofanyotherleadingnationalpharmaceticalmarket.China,ontheotherhand,wastheonlycountryamongthesecountriesshowinganactualdecreaseofthemarket.ReadmoreNote(s):WorldwideSource(s):IQVIAPharmaceuticalspendingpercapitainselectedcountriesin2022(inU.S.dollars)Pharmaceuticalspendingpercapitainselectedcountries2022PercapitaspendinginU.S.dollars600

80002004001,0001,2001,4001,600UnitedStatesGermany1,4321,042Canada(2022)Korea(2022)SwitzerlandFrance914803803766765AustriaItaly(2022)GreeceLuxembourg(2022)Belgium748740706649632625Iceland(2022)Ireland5Description:PharmaceuticalspendingpercapitainCanadastoodat914U.S.dollars,in2022.Incomparison,theUnitedStatesreportedpercapitaspendingof1,432U.S.dollars(2021).Asformedicalgoodsandservicesingeneral,theU.S.isamongthecountrieswithhighesthealthcostsworldwide.ThehighercostsintheUnitedStatesareparticularlyobviouswhencomparedtootherhigh-income,developedcountries.ReadmoreNote(s):Worldwide;2022Source(s):OECDDrugproductssalesdistributioninselectedcountriesin2022,bytherapeuticclassDrugproductssalesdistributionworldwidebycountryandtherapyarea2022Alimentary

tract

andmetabolismBlood

and

blood

formingorgansCardiovAustraliaCanadaFrance12.1%14.9%8.7%5.3%4.4%8.6%8.8%9%GermanyItaly10.8%10.4%11.3%11.2%11%Spain6.7%9.7%7.8%SwedenUnitedKingdom6Description:Thisstatisticdisplaysthedrugproductssalesdistributioninselectedcountriesin2022,sortedbytherapeuticclass.Antineoplasticsandimmunomodulatingagentsheldthehighestsalespercentageinallcountries.ReadmoreNote(s):WorldwideSource(s):IQVIA;PMPRBCHAPTER

02KeyfiguresTotalhealthexpenditureondrugsinCanadafrom2005to2023(inbillionCanadiandollars)HealthexpendituresondrugsinCanada2005-2023605047.9464341.240.438.838.44037.235.833.83433.53332.429.527.9302010026.425.123.220052006200720082009201020112012201320142015201620172018201920202021

2022*

2023*8Description:ThisstatisticdisplaysthetotalhealthexpendituresinCanadaondrugsfrom2005to2023.For2023,itwasprojectedthatthecountrywouldspendnearly48billionCanadiandollarsonpharmaceuticaldrugs.ReadmoreNote(s):Canada;*Forecast.ReadmoreSource(s):CIHIPharmaceuticalsalesfrompatentedandnon-patenteddrugsinCanadafrom2004to2022(inbillionCanadiandollars)Pharmaceuticalsalesfrompatentedandnon-patenteddrugsinCanada2004-2022PatentedNon-patented25201510519.218.417.714.217.416.717.216.816.715.615.113.813.41312.912.912.612.712.49.812.111.711.610.910.510.2109.49.29.28.88.98.77.875.64.54020042005200620072008200920102011201220132014201520162017

2018*

2019*

2020*

2021*

2022*9Description:Thisstatisticdisplaysthepharmaceuticalsalesforpatentedandnon-patenteddrugsinCanadafrom2004to2022.In2007,patenteddrugsalesinthecountrytotaled12.1billionCanadiandollars,whiletherecordhighwasin2022withsome18.4billionCanadiandollars.However,2022wasalsotheyearwhennon-patenteddrugsaleswerehigherforthefirsttimeintheprovidedperiod.ThepharmaceuticalindustryinCanadabothdevelopsandmanufacturesbrandnameandgeneric[...]

ReadmoreNote(s):Canada;*Non-patentedvaluewascalculatedbasedongivenfigures.ReadmoreSource(s):PMPRBTotalpharmaceuticalR&DexpendituresinCanadafrom2004to2022(inbillionCanadiandollars)SpendingonR&DfrompharmaceuticalindustryinCanada2004-20221.41.21.00.80.60.40.20.01.331.311.271.231.211.181.170.990.940.920.920.910.890.890.870.870.820.80.79200420052006200720082009201020112012201320142015201620172018201920202021202210Description:In2022,totalR&Dspendingintheindustryreachedsome0.91billionCanadiandollars,whilethehighestamountinthegivenperiodwasin2007withsome1.33billiondollars.ThisstatisticdisplaysthetotalresearchanddevelopmentexpendituresfromthepharmaceuticalindustryinCanadabetween2004to2022.ThepharmaceuticalindustryinCanadabothdevelopsandmanufacturesbrandnameandgenericpharmaceuticals.ReadmoreNote(s):CanadaSource(s):PMPRBEmploymentinCanadianpharmaceuticalindustrymanufacturingfrom2005to2022EmploymentinpharmaceuticalmanufacturinginCanada2005-202235,00033,12832,51331,53130,85330,03229,870

29,80428,91430,000

28,67325,00028,70028,49428,13827,20927,30226,979

26,98326,71025,93420,00015,00010,0005,000020052006200720082009201020112012201320142015201620172018201920202021202211Description:In2022,the12-monthaveragenumberofemployeesintheCanadianmanufacturingpharmaceuticalindustrystoodatover33thousand.ThisstatisticdisplaystheaverageemploymentnumbersinthemanufacturingportionofthepharmaceuticalindustryinCanadafrom2005to2022.ThepharmaceuticalindustryinCanadabothdevelopsandmanufacturesbrandnameandgenericpharmaceuticals.ReadmoreNote(s):CanadaSource(s):Innovation,ScienceandEconomicDevelopmentCanada;StatCanPharmaceuticaltradebalanceofCanadafrom2004to2022(inbillionCanadiandollars)PharmaceuticalindustrytradebalanceofCanada2004-20220-2-4-6-8-5.5-5.5-5.6-5.7-5.9-5.9-6.4-7-7.1-7.2-7.7-8-8.4-8.5-8.7-10-12-14-16-9.4-10.32020-13.42021-152004200520062007200820092010201120122013201420152016201720182019202212Description:ThisstatisticdisplaystheCanadianpharmaceuticaltradebalancefrom2004to2022.In2022,theindustryreportedatradedeficitofsome15billionCanadiandollars.ThepharmaceuticalindustryinCanadabothdevelopsandmanufacturesbrandnameandgenericpharmaceuticals.ReadmoreNote(s):CanadaSource(s):Innovation,ScienceandEconomicDevelopmentCanada;StatCanLeading10pharmaceuticalcompaniesinCanadain2022,byrevenue(inbillionCanadiandollars)ToppharmaceuticalcompanieslocatedinCanada2022,byrevenueRevenueinbillionCanadiandollars2.0

2.50.00.51.01.53.03.54.04.55.0Johnson&JohnsonMerck4.731.771.75NovartisAbbVie1.711.621.481.461.361.351.31NovoNordiskAstraZenecaPfizerBayerApotexGlaxoSmithKline13Description:TotalpharmaceuticalsalesinCanadacametoabout34billionU.S.dollarsin2022.Ofthis,U.S.-baseddiversifiedhealthcompanyJohnson&Johnsongeneratedover4.7billiondollars.Thus,J&Jheldthelargestsinglemarketsharewithover12percent.Withasignificantdistance,U.S.-basedcompanyMerckwasrankedsecondgeneratingrevenuesofaround1.8billionCanadiandollars.ReadmoreNote(s):CanadaSource(s):Innovation,ScienceandEconomicDevelopmentCanada;IQVIACHAPTER

03RegionalcomparisonPrescriptiondrugexpenditureinCanadabypublicdrugplanin2021/2022(inmillionCanadiandollars)PrescriptiondrugexpenditureinCanadabypublicdrugplan2021/2022ExpenditureinmillionCanadiandollars2,000

3,000

4,00001,0005,0006,0007,0008,0009,000AlbertaBritishColumbiaManitoba1,1991,545533323191359NewBrunswickNewfoundlandandLabradorNovaScotiaOntario8,324PrinceEdwardIslandSaskatchewan60616Yukon

1915Description:Alberta'spublicdrugplanspentsome1.2billionCanadiandollarsonprescriptiondrugs.ThisstatisticdepictstheprescriptiondrugexpendituresinCanadainfiscalyear2021/2022,byselectedpublicdrugplan.ReadmoreNote(s):NorthAmerica,Canada;FY2021/2022Source(s):CIHI;PMPRBDistributionofcurrentpharmaceuticalR&DexpendituresinCanadafrom2017to2022,byregionPharmaceuticalcurrentR&DspendingdistributioninCanadabyregion2017-202220172018201920202021202260%50%40%30%20%10%0%52.3%50.9%51%47.4%49.1%47.6%34%32.7%29.8%28.3%28.4%26.3%21.1%19.9%18.3%18.4%17.6%15%2.3%2.4%2.2%1.9%1.5%1.5%0%

0%

0.1%

0%

0%

0%TerritoriesAtlanticprovincesQuebecOntarioWesternprovinces16/statistics/422614/pharmaceutical-randd-spending-distribution-in-canada-by-regionThisstatisticdisplaysthedistributionofcurrentresearchanddevelopmentexpendituresofthepharmaceuticalindustryinCanadafrom2017to2022,byregion.In2022,Quebeccontributedsome30percentofthecountry'spharmaceuticalR&Dspending.ReadmoreNote(s):CanadaSource(s):PMPRBDrugexpenditurepercapitainCanadabyprovincein2023(inCanadiandollars)MedicationspendingpercapitainCanadabyprovince2023PercapitaexpenditureinCanadiandollars400

600

80002001,0001,2001,4001,600QuebecNewfoundlandandLabradorNewBrunswickNovaScotia1,358.51,336.71,3161,297.61,259.11,203.8OntarioNorthwestTerritoriesYukon1,1701,163.81,159.4PrinceEdwardIslandAlbertaSaskatchewanNunavut1,112.91,104.6Manitoba1,027.9BritishColumbia947.817Description:In2023,drugexpendituresinOntarioaveragedatsome1,259Canadiandollarsperperson.Percapitahealthexpenditurestendtodifferamongprovincespartiallyduetodifferencesinagedistribution.ThisstatisticshowsaforecastofthedrugexpenditurepercapitaineachCanadianprovincein2023.ReadmoreNote(s):Canada;asofNovember2023;*ForecastedReadmoreSource(s):CIHIGenericshareoftotalnumberofprescriptionsinCanadabyprovincein2022ProvincialgenericmedicineprescriptionmarketshareinCanada2022Shareofprescriptions30%

40%0%10%20%50%60%70%80%90%ManitobaQuébec78.4%78.3%NovaScotia76.8%76.5%74.2%SaskatchewanNewBrunswickNewfoundlandandLabradorPrinceEdwardIslandAlberta73.5%73.5%72.8%72.6%BritishColumbiaOntario70%18Description:ThisstatisticshowsthegenericshareofthetotalnumberofprescriptionsinCanadabyprovincein2022.Manitobahadthehighestgenericssharewithinitsprescribeddrugsmarketwith78.4percentinthatyear.ReadmoreNote(s):CanadaSource(s):CanadianGenericPharmaceuticalAssociation;IQVIACHAPTER

04ProductsandpricesLeading10pharmaceuticalproductsinCanadain2022,bysales(inmillionCanadiandollars)ToppharmaceuticalproductsinCanadabysales2022SalesinmillionCanadiandollars400

60002008001,0001,200Ozempic(NovoNordisk)Remicade(Janssen)Stelara(Janssen)1,044920821Eylea(Bayer)706Keytruda(Merck&Co.)Humira(AbbVie)621585Jardiance(Boehringer)Imbruvica(Janssen)Vyvanse(Takeda)Eliquis(BMS)39837637535820Description:In2022,AbbVie'sHumirageneratedsome585millionCanadiandollarsinsalesinCanada,makingittothesixthpositionamongCanada'stop10drugsbasedonsales.Thisstatisticdisplaysthe10leadingpharmaceuticalproductsinCanadain2022,bysales.ReadmoreNote(s):CanadaSource(s):Innovation,ScienceandEconomicDevelopmentCanada;IQVIAAveragecostperbeneficiaryofselectprominentdrugsinCanada'spublicdrugplansin2021/2022(inCanadiandollars)CostperbeneficiaryofselectdrugsinCanada'spublicdrugplans2021/2022AveragecostinCanadiandollarsperprescription010,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

100,000Trikafta(elexacaftor/tezacaftor/ivacaftor)Ibrance(palbociclib)89,05446,066Ocrevus(ocrelizumab)26,178Skyrizi(risankizumab)17,91811,1289,180Biktarvy(tenofoviralafenamide,bictegravir,emtricitabine)Eylea(aflibercept)Entresto(sacubitril/valsartan)Ozempic(semaglutide)2,2441,829975Eliquis(apixaban)Jardiance(empagliflozin)82621Description:Asoffiscalyear2021/2022,prescriptiondrugTrikafta(elexacaftor/tezacaftor/ivacaftor)costonaveragesome89thousandCanadiandollarsperbeneficiary.Trikaftaisamedicineusedtotreatcysticfibrosis.

ReadmoreNote(s):Canada;FY2021/2022Source(s):CIHI;PMPRBTopbiologicdrugsbyshareoftotaldrugcostswithinselectCanadianpublicdrugplansin2021/2022TopbiologicdrugsbyshareoftotaldrugcostsinCanadianpublicplans2021/2022Shareoftotaldrugcostsinpercent6%

8%

10%0%2%4%12%14%16%18%20%22%Totaltop10biologics19.7%Eylea3.8%Humira3.3%3.2%RemicadeandinfliximabbiosimilarsOzempic2.3%2%LucentisEnbrelandetanerceptbiosimilars1.1%Prolia1.1%1%LantusandinsulinglarginebiosimilarsEntyvioTresiba1%0.8%22Description:ThisstatisticdepictsthetopbiologicdrugsbyshareoftotaldrugcostswithinselectCanadianpublicdrugplansin2021/2022.ToplistedbiologicdrugwasEylea(aflibercept)witha3.8percentshareoftotaldrugcoststhatyear.

ReadmoreNote(s):Canada;FY2021/2022Source(s):CIHI;PMPRBCostsofbiologicdrugsinselectCanadianpublicdrugplansin2021/2022(inmillionCanadiandollars)BiologicdrugcostsinselectCanadianpublicdrugplansin2021/2022CostinmillionCanadiandollars1,00005001,5002,0002,500AlbertaBritishColumbiaManitoba351436.7179NewBrunswick80.942.277.3NewfoundlandandLabradorNovaScotiaOntario2,021.9PrinceEdwardIslandSaskatchewan17.3221.8Yukon

4.423Description:WithinAlberta'spublicdrugplan,biologicdrugcostsamountedtoaround351millionCanadiandollars.ThisstatisticdepictsthedrugcostofbiologicsinselectCanadianpublicdrugplansinfiscalyear2021/2022.ReadmoreNote(s):Canada;FY2021/2022Source(s):CIHI;PMPRBPatenteddrugspriceindexchangesinCanadafrom1988to2022ChangesinpriceindexofpatenteddrugsinCanada1988-2022Annualpriceindexchange-0.8%2022-0.6%-0.4%-0.2%0.0%0.2%0.4%0.6%0.8%1.0%1.2%0.8%2021202020192018201720162015201420132012201120100.4%0.6%1%-0.3%-0.2%-0.6%0%0%-0.1%-0.1%0.3%-0.5%24Description:Thisstatisticdisplaysthechangesinthepriceindexofthepatenteddrugsfrom1988to2022.In1996,thepriceindexwasloweredby2.2percentandfrom2011to2015,thepricesofthedrugsremainedalmostunchanged.Forthelatestyearwithavailabledata,2022,theindexshowedanincreaseof0.8percent.ReadmoreNote(s):CanadaSource(s):PMPRB;StatCanAverageforeign-to-Canadianpriceratioforpatenteddrugsasof2022AveragepriceratioCanadiantoforeigndrugprices2022Foreign-to-CanadianPriceRatio0.00.51.01.52.02.53.03.54.0UnitedStatesCanada3.5711MexicoSwitzerlandSpain0.970.91Italy0.90.9GermanyNewZealandIreland0.880.870.87AustriaNorway0.84UnitedKingdomBelgium0.840.8225Description:ThisstatisticdisplaysthepatenteddrugaveragepriceratioofforeigntoCanada,asof2022.TheratioofpricesintheUnitedStatestoCanadawas3.57,whichindicatesthatthepricesofpatenteddrugsintheUnitedStatesweremorethanthreeandahalftimeshigherthaninCanada.ReadmoreNote(s):Worldwide,CanadaSource(s):IQVIA;OECD;PMPRBCHAPTER

05TherapyclassesLeadingtherapeuticclassespurchasedbyhospitalsinCanadain2022(inmillionCanadiandollars)Canadianhospitals'toptentherapeuticclassespurchasedin2022PurchasesinmillionCanadiandollars1,000

1,500

2,00005002,5003,0003,5003,501.34,000OncologyBiologicals838.4Anti-virals386.6Hematinics234.6229.7120.2HemostaticmodifiersAnti-infectives,systemicPsychotherapeuticsDiverse,ethics105.1104.194.8NeurologicaldisordersOphthalmics90.227Description:During2022,Canadianhospitals'highestmedicationpurchasewasoncancertreatmentdrugs,withsome3.5billionCanadiandollarsspent.Incomparison,thesecondhighestamountspentondrugsbyhospitalswasabout838millionCanadiandollarsforbiologicals.ReadmoreNote(s):CanadaSource(s):IQVIAGrowthofthetoptherapeuticclassespurchasedbyhospitalsinCanadain2022comparedtopreviousyearChangeinCanadianhospitals'toptherapeuticclasspurchases2022Changecomparedto202020%

30%-10%Anti-virals0%10%40%50%60%70%58.5%OncologyBiologicals19.6%18.1%PsychotherapeuticsDiverse,ethics5.9%5.1%Hematinics1.6%0.1%OphthalmicsAnti-infectives,systemicHemostaticmodifiers-2.6%-4.8%Neurologicaldisorders

-6.5%28Description:In2022,Canadianhospitalsspentnearly20percentmoreondrugsfortreatingcancerthanin2021.Ontheotherhand,2.6percentlesswasspentonsystemicanti-infectives.ThisstatisticshowsthepercentchangeinthetoptentherapeuticclassespurchasedbyhospitalsinCanadain2022.ReadmoreNote(s):CanadaSource(s):IQVIAToptherapeuticclassespurchasedbydrugstoresinCanadain2022(inmillionCanadiandollars)Canadiandrugstores'topdrugtherapeuticclassespurchases2022PurchasesinmillionCanadiandollars1,500

2,00005001,0002,5003,0003,5003,419.93,352.74,000Anti-arthriticsDiabetestherapyImmunologicagentsPsychotherapeuticsOncology2,811.32,708.32,171.8RespiratorytherapyCardiovascularsOphthalmics1,777.81,457.71,407.81,357.3NeurologicaldisordersAnti-virals1,061.929Description:During2022,thetopdrugtherapeuticclassofdrugstorepurchaseswasanti-arthriticmedicationsatsome3.42billionCanadiandollars,followedbydiabetestherapieswith3.35billionCanadiandollarsinpurchases.ThisstatisticshowsthetoptentherapeuticclassesofdrugstorepurchasesinCanadain2022.ReadmoreNote(s):CanadaSource(s):IQVIAGrowthoftoptherapeuticclassespurchasedbydrugstoresinCanadain2022comparedtopreviousyearChangeinCanadiandrugstores'topdrugtherapeuticclasspurchases2022Changecomparedto20205%

10%-5%0%15%20%25%DiabetestherapyImmunologicagentsOncology20.7%16.8%13.7%PsychotherapeuticsRespiratorytherapyNeurologicaldisordersCardiovascularsOphthalmics9.2%8%7.2%5.1%4.4%Anti-arthritics-0.7%-1.4%Anti-virals30Description:InCanada,drugstorepurchasesofimmunologicalagentsincreasedbyaround17percentfrom2021to2022,whereaspurchasesofanti-viralsdecreasedby1.4percent.ThisstatisticdepictsthepercentchangeindrugstorepurchasesofthetoptenmedicationclassesinCanadain2022.ReadmoreNote(s):CanadaSource(s):IQVIACHAPTER

06GenericsCanadianprescribedgenericmedicinesalesfrom2006to2022(inbillionCanadiandollars)GenericRxmedicinesalesinCanada2006-202298768.447.26.4465.865.785.765.725.435.415.465.275.235.294.75432103.893.2620062007200820092010201120122013201420152016201720182019*

2020*

2021*

2022*32Description:ThisstatisticshowsthesalesdevelopmentofgenericmedicinesintheCanadianprescriptiondrugmarketfrom2006to2022,inbillionCanadiandollars.Salesreachedthemaximumin2022withavalueof8.4billionCanadiandollars.

ReadmoreNote(s):Canada;*Calculatedbasedonprovideddata.ThisstatisticisassembledfromseveraleditionsofCGPA'sreports.ReadmoreSource(s):CanadianGenericPharmaceuticalAssociation;IQVIACanadiangenericandbrandnamemedicineaverageretailpriceperprescriptionfrom2004to2022(inCanadiandollars)GenericandbrandnamemedicineaverageretailpriceinCanada2004-2022BrandnamemedicineGenericmedicine14012010080125.77120.22114.22111.24105.1599.994.6290.3186.2782.5477.0373.3172.02

71.9169.367.4466.164.8460.61604026.09

26.45

26.13

26.2324.56

24.9524.523.7623.5822.1422.3321.29

20.5120.8320.42

20.1919.7719.319.19200200420052006200720082009201020112012201320142015201620172018201920202021202233Description:ThisstatisticshowsthecomparisonofaverageretailpricedevelopmentforbrandnameandthegenericmedicinesinCanadafrom2004to2022,perprescription.In2022,theaverageretailpriceofbrandnameprescriptiondrugswasover100Canadiandollarshigherthantheaverageretailpriceofgenericmedicines.Ingeneral,thepricedifferencebetweenthesedrugtypesincreaseddramaticallyovertheshownperiod.

ReadmoreNote(s):CanadaSource(s):CanadianGenericPharmaceuticalAssociation;IQVIAGenericsshareofmedicineprescriptionsinCanadafrom2006to2022GenericmedicineprescriptionmarketshareinCanada2006-202280%74.4%73.6%73%73%71.8%70.2%

70.6%68.6%70%60%50%40%30%20%10%0%67.1%65.6%62.9%60.1%57.5%55%51.8%48.1%44.8%2006200720082009201020112012201320142015201620172018201920202021202234Description:ThisstatisticshowsthegenericsmarketsharebasedonprescriptionsinCanadafrom2006to2022.Thechangesintheprovincialandprivatesectordrugprogramcostshaveincreasedthemarketshareofgenericprescription.In2022,themarketshareofgenericdrugsinCanadaamountedtoover74percent.ReadmoreNote(s):CanadaSource(s):CanadianGenericPharmaceuticalAssociation;IQVIAGenericsshareofprescribeddrugcostsinCanadafrom2006to2022GenericmedicineshareofCanada'sprescriptioncosts2006-202230%25.6%24.5%

24